Exclusive! Marketing Exclusivities for Prescription Drugs

Understand the parameters of non-patent marketing exclusivities for prescription drugs in the United States.

Read now »

Related Content

• Hatch-Waxman Safe Harbor Checklist
  Refer to this checklist when advising pharmaceutical companies about conducting research studies required for FDA approval of a generic drug.

• Plaintiff's Interrogatories in Hatch-Waxman Patent Litigation
  Use this template as a starting point for preparing interrogatories for service on a generic challenger accused of infringement under the Hatch-Waxman Act.

Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.

• Explore the Practical Guidance Journal Spring 2024 Edition, featuring guidance on protecting attorney-client privilege and work product in a generative AI world, using AI to manage the attorney client relationship, an overview of privacy regulations in the United States, and a primer on the new Corporate Transparency Act requirements.
• Generative Artificial Intelligence (AI) Resource Kit is a frequently updated collection of current Practical Guidance materials on generative AI, ChatGPT, and similar tools.
• Listen Up! The Practical Guidance and Law360 Podcasts Resource Kit features interviews with industry-leading attorneys on cutting edge issues in the law: NFTs, Cannabis, COVID-19, and more.

PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB

Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+